-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $170

Benzinga·03/10/2026 12:43:09
Listen to the news
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $180 to $170.